SirBillybob

Last year I came across a few cross-affiliated fellows, at 50-ish in Thermas yet 150-ish via ad sites, the latter obviously more the full hour. Not surprising that some degree of gap closure would evolve. 75 in a structured environment with an expanded array of choice seems reasonable. What I am currently curious about is how much the apparently large volume of visiting providers with site ads might be supplementing in this manner, as some work in Spain seasonally, temporarily, even in cycles.

I had also been Vaccinia-experienced (Smallpox vaccinated), long before your travel-related uptake, and chose to receive only the single dose of MVA-BN some 24 months ago although I had access to the booster, administered subQ, if so desired. Along with the historical residual protection concept was the existence of evidence at the time suggesting that a delayed 2nd dose of MVA-BN yielded a stronger immunogenic response.
Currently a very detailed paper has come out supporting the idea that a 2nd dose taken at this time two years on, obviously depending on whether a new incidence wave emerges, is actually better than having followed the initial recommended two-dose regimen. The single- vs two-dose efficacy difference at the current two-year point is not enormous because antibody decay following the second dose is more rapid. 
The above may be an important consideration for those MVA-BN-naive and considering vaccination uptake with or without the re-emergence of problematic new incidence. Interestingly, for those spared infection to date due to lack of pathogen exposure, two doses in 2022 appears to be less beneficial and to have been somewhat superfluous compared to an as yet delayed second dose, the benefit equivalence of which may justify a third upcoming dose some 23 months following second dose.
I am still holding off on the second MVA-BN dose, balanced delicately against prospective case incidence patterns. 
D below is efficacy trajectory projected over a decade of time; shading is confidence interval.
A, B, C are immunogenicity graphs with y axis demarcation gaps depicted on a log scale 0, 10, 100, 1,000.

Off topic, but I just discovered Tubi for older Nick Galitzine films. Seems to be a free supplement to Apple. He is a co-lead in Handsome Devil playing a student and Andrew Scott plays a secondary role as a teacher. (I just edited out some adjectives due to their plot-spoiler status.😉)

I am attracted to Alec Secareanu from God’s Own Country, so every once in awhile I search to see if he’s been in anything newly available.
That’s how I started something in the middle of the night on Tubi without knowing what it was… and I stayed with it despite the brutal subject matter because it was quite well done.
Doing Money is a British television drama, written by Gwyneth Hughes and directed by Lynsey Miller, that was first broadcast on BBC Two. Focusing on the subject of modern slavery in the sex trade, the film, starring Anca Dumitra and Allen Leech, is based upon the fact-based novel Slave by Jason Johnson.
The film documents the story of ‘Ana’, a Romanian student training to be a nurse who is kidnapped in broad daylight from the streets of London and ordered to work as a prostitute in a number of brothels in Ireland and Northern Ireland. The film was broadcast as part of the BBC’s Why Slavery? season, to coincide with International Anti Slavery Day.
Anca Dumitra said of her role as Ana; “Ana is a truly remarkable person, someone who has survived endless abuse with courage and determination, a real-life hero. I have been deeply moved by her story and it’s an honour to play her in Doing Money. This is a story that needs to be seen.”
Allen Leech added; “I’m delighted to be part of telling this moving and important true story. Doing Money, Ana’s experience, shines a light on the shocking truth of human trafficking and slavery in Britain. DI Dougie Grant was one of the key officers at the centre of the original investigation. It’s a real privilege to play him.”
Alison Graham of the Radio Times wrote; “After watching Gwyneth Hughes’s fact-based drama Doing Money, I went home stifled by a cloud of misery that couldn’t be dispersed, even by the repeats of ancient Big Bang Theories I watched long into the evening just to try to flush the horror from my system. I found Doing Money so overwhelming – the true story of Ana, a young Romanian woman working as a cleaner in Britain who was abducted by a trafficking gang from a street in Wood Green London and forced into sex slavery. I was harrowed as she was repeatedly brutalised into submission by a series of men who treated her savagely.”
Viewers described the film as “horrific”, “disturbing”, “harrowing” and “heartbreaking.”

I tuned in to the first episode immediately upon release, as I often do for determining whether a show goes to watch-or-pass, and ended up binging the series. The final scene is rich. Emmy buzz occurring; nominations in two months. 

I tuned in to the first episode immediately upon release, as I often do for determining whether a show goes to watch-or-pass, and ended up binging the series. The final scene is rich. Emmy buzz occurring; nominations in two months. 

I tuned in to the first episode immediately upon release, as I often do for determining whether a show goes to watch-or-pass, and ended up binging the series. The final scene is rich. Emmy buzz occurring; nominations in two months. 

I tuned in to the first episode immediately upon release, as I often do for determining whether a show goes to watch-or-pass, and ended up binging the series. The final scene is rich. Emmy buzz occurring; nominations in two months. 

Has anyone watched “Baby Reindeer”? It’s based on a true story about a bartender who’s perusing a career as a comedian but finds himself being stalked by a strange woman he feels sorry for.
It’s creepy but most enjoyable. Covers just about every sexual topic. One being the sexual abuse the man faced perusing his career. The episodes are fast moving. 

As long as he accepts cheeks bouncing on him. 

As long as he accepts cheeks bouncing on him. 

Just temporary signage as negotiated with the movie production company, among other external set alterations. Subbing for 1987 San Diego Gaslamp Quarter.

As long as he accepts cheeks bouncing on him. 

As long as he accepts cheeks bouncing on him. 

Just temporary signage as negotiated with the movie production company, among other external set alterations. Subbing for 1987 San Diego Gaslamp Quarter.

Binged Ripley on Netflix yesterday and today. 8 episodes. Couldn’t stop, but nice way to wait out a nasty Spring snowstorm in front of the fireplace. Some Fargo-like elements added for humour, one in particular very funny.
If you can get past Flynn at age 41 and Scott at age 47, though. Law and Damon were late 20’s. I don’t know how much Ripley ages thru Highsmith’s sequels. I do believe the plan is further adaptation. 

Was there ever a "good" time?……grin

Re: thread merging. Thanks for inserting the year-old topic. I had been aware of it. I consciously started the new topic as it is specific to the one bacterial STI [gonorrhea] most concerning for its increasing standard treatment failure rate, as well as adds vaccination concepts (eg, Bexsero) not included in the previous discussion but that had been referenced in at least one other thread on the board. Moreover, the previous topic discussion is antimicrobial resistance focused and requires unpacking the merits and liabilities of DoxyPEP alone across a broader range of viral and bacterial diseases. There are also several separate threads more relevant to gonorrhea alone over the past year, including vaccination as mentioned, newly emerging first-in-class oral treatment medications, and acute disseminated gonococcal disease. Anybody wishing a more integrative reading experience is advised to use the search term ‘gonorrhea’ on the board. 

My biggest concern at this point is for the speed at which the DoxyPREP regimen may accelerate the resistance of chlamydia and syphilis.
Obviously, it is a bit of a summary article and not a not a journal article on the research data, but I am gathering that while chlamydia remained relatively constant, starting at 88% with the initial DoxyPREP trial and 89% a year in, syphilis was initially 87% and fell to 79% a year in.
If the big picture observations are that:
- DoxyPREP only reduces gonorrhea infection rate by 33%;
-studies show evidence that vaccination with meningococcal B by itself reduce gonorrhea by 30 - 50%;
-current scientific theory tells us that short bursts of antibiotics contribute resistance;
-antibiotics take a toll on body systems; and
-we already know that Benzathine Penicillin G is already a better treatment for syphilis than doxycycline
I would place my faith in vaccination for gonorrhea, treat syphilis with the superior antibiotic, and treat both gonorrhea and chlamydia with a FULL course of Doxycycline as needed.
And of course, pray to the pharmaceutical and profit gods for vaccines specific for all three!

Re: thread merging. Thanks for inserting the year-old topic. I had been aware of it. I consciously started the new topic as it is specific to the one bacterial STI [gonorrhea] most concerning for its increasing standard treatment failure rate, as well as adds vaccination concepts (eg, Bexsero) not included in the previous discussion but that had been referenced in at least one other thread on the board. Moreover, the previous topic discussion is antimicrobial resistance focused and requires unpacking the merits and liabilities of DoxyPEP alone across a broader range of viral and bacterial diseases. There are also several separate threads more relevant to gonorrhea alone over the past year, including vaccination as mentioned, newly emerging first-in-class oral treatment medications, and acute disseminated gonococcal disease. Anybody wishing a more integrative reading experience is advised to use the search term ‘gonorrhea’ on the board. 

Re: thread merging. Thanks for inserting the year-old topic. I had been aware of it. I consciously started the new topic as it is specific to the one bacterial STI [gonorrhea] most concerning for its increasing standard treatment failure rate, as well as adds vaccination concepts (eg, Bexsero) not included in the previous discussion but that had been referenced in at least one other thread on the board. Moreover, the previous topic discussion is antimicrobial resistance focused and requires unpacking the merits and liabilities of DoxyPEP alone across a broader range of viral and bacterial diseases. There are also several separate threads more relevant to gonorrhea alone over the past year, including vaccination as mentioned, newly emerging first-in-class oral treatment medications, and acute disseminated gonococcal disease. Anybody wishing a more integrative reading experience is advised to use the search term ‘gonorrhea’ on the board. 

Yes.

Updated/revised DoxyVAC trial results a year later; reduced benefit from DoxyPEP and negligible benefit from Bexsero vaccine.
https://www.poz.com/article/meningococcal-vaccine-significantly-reduce-gonorrhea-risk

Or 99% are evolved and fit the profile of a customer capable of satisfaction with the 50-Euro-a-pop brothel playbook. Sexually mature and flexible homophiles equally open to insertive and receptive pleasure, not hampered by constrictive specifications, unencumbered by puerile notions of sexual position hierarchy. Trading off choice, perhaps optimal standards and preference, for convenience and the general life benefits of adaptation.
The average new parent will quickly realize that their toddler is a douche, insufficiently developed to be successfully cajoled regarding its laundry list. The best approach is to simply convey that you get what you get and you don’t get upset. 

Updated/revised DoxyVAC trial results a year later; reduced benefit from DoxyPEP and negligible benefit from Bexsero vaccine.
https://www.poz.com/article/meningococcal-vaccine-significantly-reduce-gonorrhea-risk